Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and Completion and Preliminary Analysis of OA-21 Trial 12-Week Pain Results
April 18, 2024 06:00 ET
|
Biosplice Therapeutics, Inc.
Presentation of OA-07 Phase 3 Long-Term Results for Lorecivivint and Preliminary Analysis of OA-21 Trial 12-Week Pain Results
Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program
March 08, 2024 13:36 ET
|
Biosplice Therapeutics, Inc.
Biosplice announced today that its collaboration with The Roskamp Institute has been awarded funding by the US Department of Defense.
Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial for Lorecivivint for the Treatment of Knee Osteoarthritis
November 13, 2023 06:00 ET
|
Biosplice Therapeutics, Inc.
Biosplice Therapeutics Inc. presents results of OA-07 Long-Term Extension Trial for its knee OA drug candidate, lorecivivint.
Biosplice Announces Interim Data from Phase 3 Long-Term Extension Clinical Trial in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial
December 15, 2022 09:00 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule...
Biosplice Announces Data from Recent Clinical Trials in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial
November 11, 2022 09:00 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule...
Biosplice Therapeutics Announced New Clinical Data for Cirtuvivint (SM08502) at the European Society for Clinical Oncology Meeting
September 29, 2022 09:00 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major...
First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology
November 17, 2021 09:15 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major...
Biosplice Licenses Development and Commercialization Rights for Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Haisco for the People’s Republic of China
September 15, 2021 09:00 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO and CHENGDU, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase...
Biosplice Publishes Phase 2B Lorecivivint Analysis Showing Clinically Meaningful Benefits to Knee Osteoarthritis Patients
July 22, 2021 10:10 ET
|
Biosplice Therapeutics, Inc.
Lorecivivint post-hoc analysis reveals significantly increased likelihood of symptom improvements for knee osteoarthritis compared to placebo SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Biosplice...
Dave Johnson Joins Biosplice Therapeutics Board of Directors
June 21, 2021 09:15 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for...